Format
Sealed research vial
Trust signal
COA-backed inventory
99%+ Purity
Lab-grade supply. Limited AU stock.
A$279
Select options below
Size
Select one
Select your preferred options to continue.
Fast AU dispatch, tracked delivery, and documentation-ready inventory.
Why labs buy from APL
High purity, consistent supply, and fast AU-wide dispatch.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
LL-37 is a 37-residue human cathelicidin antimicrobial peptide (the C-terminal domain of hCAP18), studied in membrane-disruption and innate-immune signalling assay models.
Research using LL-37 typically separates its direct membrane-disrupting activity from its receptor-mediated immunomodulatory signalling, using FPRL1/FPR2 antagonists to attribute readouts to the receptor pathway. Because high salt promotes immediate aggregation, careful buffer control is central to reproducible results.
Browse Inventory
In research literature, LL-37 is generally treated as a 37-residue human cathelicidin antimicrobial peptide (the C-terminal domain of hCAP18), studied in membrane-disruption and innate-immune signalling assay models. LL-37 is a 37-residue human cathelicidin antimicrobial peptide (the C-terminal domain of hCAP18) that adopts an amphipathic α-helix at physiological ionic strength. It disrupts bacterial membranes, signals through formyl-peptide receptor-like 1 (FPRL1/FPR2), and modulates innate immune pathway outputs in human cell models. Its activity and aggregation state are strongly ionic-strength dependent, which makes buffer conditions a critical experimental variable.
Research using LL-37 typically separates its direct membrane-disrupting activity from its receptor-mediated immunomodulatory signalling, using FPRL1/FPR2 antagonists to attribute readouts to the receptor pathway. Because high salt promotes immediate aggregation, careful buffer control is central to reproducible results. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether LL-37 behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.
Potential research applications for LL-37 should be framed strictly in analytical and laboratory terms. Typical reasons a team might review this product page include:
Handling decisions should always follow the vial label, internal SOPs, and any product-specific documentation. A conservative laboratory baseline for LL-37 is:
If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.
When teams compare LL-37 with Klow, Glow, and NAD+, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
It brings together 2 labelled variants: 5mg and 10mg, current pricing context, stock visibility, COA access, and internal links to related catalogue pages so a laboratory buyer can review the material from a single reference URL.
LL-37 is generally discussed as a 37-residue human cathelicidin antimicrobial peptide (the C-terminal domain of hCAP18), studied in membrane-disruption and innate-immune signalling assay models. The most relevant background is sequence behaviour, pathway or receptor context where documented, and analytical consistency under controlled laboratory conditions.
Use the label, COA, and internal SOPs as the primary guide. In general, store the material under controlled laboratory conditions, minimise avoidable environmental exposure, and keep variant tracking records current.
This page links the broader COA library when a product-specific document is not attached. Laboratories should use the published documentation set that is currently available for the listing.
No. The page should be interpreted strictly in a research and laboratory context. It does not provide dosage guidance, treatment claims, or human or animal use instructions.
